Objective To assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes.Design Multicentre, double blind, randomised, placebo controlled trial.Setting 16 centres in mainland China from 12 June 2020 to 31 January 2023.Participants 328 patients with type 2 diabetes aged 20-70 years, with body mass index >25 and diabetes duration of <6… Continue reading #Dapagliflozin plus calorie restriction for remission of type 2 #diabetes: multicentre, double blind, randomised, placebo controlled trial
Tag: dapagliflozin
Serial Assessment of High-Sensitivity Cardiac #Troponin and the Effect of #Dapagliflozin in Patients with Heart #Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial
Circulating high-sensitivity cardiac troponin T (hsTnT) predominantly reflects myocardial injury, and higher levels are associated with a higher risk of worsening heart failure (HF) and death in patients with HF with reduced ejection fraction (HFrEF). Less is known about the prognostic significance of changes in hsTnT over time, the effects of dapagliflozin on clinical outcomes… Continue reading Serial Assessment of High-Sensitivity Cardiac #Troponin and the Effect of #Dapagliflozin in Patients with Heart #Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial
Extrapolating Long-term Event-Free and Overall Survival With #Dapagliflozin in Patients With #Heart Failure and Reduced #Ejection Fraction
Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results when communicating the benefits of this class of drug to patients. Objective To estimate… Continue reading Extrapolating Long-term Event-Free and Overall Survival With #Dapagliflozin in Patients With #Heart Failure and Reduced #Ejection Fraction
#Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial RESEARCH DESIGN AND METHODS… Continue reading #Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a… Continue reading Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
#Dapagliflozin in Patients with Chronic #Kidney Disease
Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.. ..The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome… Continue reading #Dapagliflozin in Patients with Chronic #Kidney Disease
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular disease. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin in the DECLARE–TIMI 58 cardiovascular outcomes trial, which included patients with type 2 diabetes both with and without established atherosclerotic cardiovascular disease and mostly… Continue reading Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
#Dapagliflozin in Patients with Heart Failure and Reduced #Ejection Fraction
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms.. A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI,… Continue reading #Dapagliflozin in Patients with Heart Failure and Reduced #Ejection Fraction
2 Medical News 